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Abstract
Objectives: Many patients with Cushing's disease (CD) require chronic pharmaco‐
therapy to control their hypercortisolism. We evaluated the efficacy and safety of 
long‐acting pasireotide during a long‐term extension study in patients with CD.
Design: Open‐label extension to a 12‐month Phase III study of long‐acting pasire‐
otide in CD (N = 150; NCT01374906).
Patients: Patients with mean urinary free cortisol (mUFC) ≤ upper limit of normal (ULN) 
or receiving clinical benefit at core study end could continue long‐acting pasireotide 
during the extension.
Results: Eighty‐one of 150 (54.0%) enrolled patients entered the extension. Median 
overall exposure to pasireotide at study end was 23.9 months; 39/81 (48.1%) pa‐
tients completed the extension (received ≥ 12 months’ treatment during the ex‐
tension and could transit to a separate pasireotide safety study). mUFC was ≤ULN 
in 42/81 (51.9%), 13/81 (16.0%) and 43/81 (53.1%) patients at extension baseline, 
month (M) 36 and last assessment. Median mUFC remained within normal limits. 
Median late‐night salivary cortisol was 2.6 × ULN at core baseline and 1.3 × ULN at 
M36. Clinical improvements were sustained over time. Forty‐two (51.9%) patients 
discontinued during the extension: 25 (30.9%) before M24 and 17 (21.0%) after M24. 
Hyperglycaemia‐related AEs occurred in 39.5% of patients. Mean fasting glucose 
(FPG) and glycated haemoglobin (HbA1c) were stable during the extension, with an‐
tidiabetic medication initiated/escalated in some patients. Sixty‐six (81.5%) and 71 
(88.9%) patients were classified as having diabetes (HbA1c ≥ 6.5%, FPG ≥ 7.0 mmol/L, 
antidiabetic medication use, or history of diabetes) at extension baseline and last 
assessment.
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1  | INTRODUC TION
Cushing's disease (CD) is a rare endocrine disorder characterized by 
overproduction of cortisol by the adrenal glands, secondary to an 
adrenocorticotropic hormone (ACTH)–secreting pituitary adenoma 
(corticotropinoma).1 CD is associated with significant multisystem 
morbidity, impaired quality of life (QoL) and increased mortality if 
inadequately treated.2,3
Selective resection of the corticotropinoma by transsphenoidal 
surgery is the first‐choice treatment for CD, but surgical success 
rates vary and depend on the expertise of the surgeon. CD persists 
in 10%‐35% of patients after surgery,4,5 while recurrence rates range 
from 15% to 66% after a variable duration of remission.6‐8 Medical 
therapy plays a prominent role in the management of persistent or 
recurrent CD, as well as in patients who are not candidates for sur‐
gery, such as those considered to be at high surgical risk and/or with 
acute complications of CD.2,8‐10
Given the chronic nature of CD, many patients require long‐term 
pharmacotherapy to achieve and maintain the goals of treatment: to 
control cortisol excess, reverse clinical features and complications of 
hypercortisolism, improve QoL, control tumour mass and increase 
life expectancy.8 A comprehensive understanding of the long‐term 
efficacy and safety of available medical treatment options is there‐
fore central to achieving optimal outcomes for patients.
Based on the results of a 12‐month Phase III study,11 a long‐act‐
ing intramuscular formulation of pasireotide suitable for monthly ad‐
ministration has been approved in the EU, United States and other 
countries worldwide for the treatment of CD.12,13 Here, we report 
the efficacy and safety of long‐acting pasireotide during a long‐term 
extension (median treatment duration: 23.9 months) to the Phase 
III study.
2  | METHODS
2.1 | Patients
This was an optional, open‐label extension to a 12‐month Phase III 
core study.11 Patients could enter the extension if they satisfied the 
following criteria at the end of the core study: mean urinary free corti‐
sol (mUFC; mean of three 24‐hour samples collected within 2 weeks) 
not exceeding the upper limit of normal (ULN; 166.5 nmol/24 h) and/
or considered by the investigator to be receiving significant clini‐
cal benefit from long‐acting pasireotide; demonstrated acceptable 
tolerability of pasireotide during the core study; and provided con‐
sent to participate in the extension.
2.2 | Study design
During the core study, adults with confirmed CD and mUFC of 
1.5‐5.0 × ULN were randomized to double‐blind pasireotide 10 or 
30 mg every 28 days; dose titration was permitted based on effi‐
cacy/tolerability.11 Patients who entered the extension continued 
long‐acting pasireotide (without interruption) at the same dose that 
they received at month 12. Pasireotide dose could be increased (5 to 
10 mg, 10 to 20 mg, 30 to 40 mg every 28 days) if mUFC > 1.0 × ULN, 
providing there was an interval of ≥3 months since last increase. 
Dose reductions were permitted at any time for tolerability (lowest 
permitted dose: 5 mg every 28 days).
During the extension, patients received long‐acting pasir‐
eotide for 12 months, at which point they continued in the study 
until an option was available to transit to a separate open‐label, 
long‐term safety study of long‐acting pasireotide (clinicaltrials.gov: 
NCT01794793; results not presented), which occurred once the 
last ongoing patient had received 12 months of treatment during 
the extension. Patients who had received an additional ≥12 months 
of treatment after the 12‐month core phase and had the option to 
enter the separate open‐label, long‐term safety study were consid‐
ered to have completed the extension. The study ended once the 
last patient had received 12 months of treatment during the exten‐
sion, and all patients had either transited to the long‐term safety 
study or discontinued treatment.
2.3 | Assessments and outcomes 
during the extension
Prespecified outcomes of the extension included the following: 
changes in mUFC, plasma ACTH, and morning serum and late‐night 
salivary cortisol (LNSC); proportion of patients with controlled 
(≤ULN) or partially controlled (>ULN and ≥50% reduction from 
baseline) mUFC; change in pituitary tumour volume, clinical signs of 
hypercortisolism and health‐related QoL (Cushing's quality‐of‐life 
questionnaire [CushingQoL]); and safety and tolerability of long‐act‐
ing pasireotide.
During the extension, the following parameters were monitored 
at 3‐month intervals: clinical signs (systolic blood pressure [SBP] and 
diastolic blood pressure [DBP], body mass index [BMI] and waist 
Conclusions: Long‐acting pasireotide provided sustained biochemical and clinical im‐
provements, with no new safety signals emerging, supporting its use as an effective 
long‐term therapy for CD.
K E Y W O R D S
Cushing syndrome, Cushing's disease, extension, hypercortisolism, pasireotide, Phase III, 
pituitary
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circumference), mUFC, morning serum cortisol, LNSC and plasma 
ACTH. Bone mineral density (BMD; left total hip and lumbar spine 
[L1‐L4]) was measured at 6‐month intervals by Lunar or Hologic 
dual‐energy X‐ray absorptiometry (DXA) instruments. Patients were 
scanned on the same DXA instrument for the duration of the study. 
Pituitary tumour volume was measured at 6‐month intervals by 
magnetic resonance imaging (MRI) and assessed by a central reader.
Safety was assessed by monitoring adverse events (AEs). AEs 
were defined using the Medical Dictionary for Regulatory Activities 
version 18.1 and graded according to Common Terminology Criteria 
for Adverse Events version 3.0. Laboratory assessments, including 
haematological/blood biochemical measurements (fasting plasma 
glucose [FPG], glycated haemoglobin [HbA1c], thyroid and liver func‐
tion tests), vital signs, gallbladder examinations and electrocardio‐
grams, were assessed as described previously.11
2.4 | Statistical methods
Efficacy and safety data are presented for patients who entered 
the extension. Analyses were performed once all patients had com‐
pleted the extension or discontinued treatment. Morning serum cor‐
tisol, LNSC, morning plasma ACTH, mUFC and clinical signs were 
analysed descriptively. Actual/percentage changes were calculated 
from core study baseline (before pasireotide initiation), and from ex‐
tension baseline (at end of core study [month 12]) for patients with 
evaluable assessments at core/extension baseline and the later time 
point. For the proportions of controlled and partially controlled re‐
sponders, two‐sided 95% confidence intervals (CIs) were calculated. 
Efficacy data are presented up to month 36 and at each patient's 
last available assessment. Safety data are presented during the core 
study (up to month 12) and extension (after month 12 until study 
end). Definitions of diabetic status (diabetic, prediabetic and normo‐
glycaemic) are included in the Appendix S1.
3  | RESULTS
3.1 | Study population
Eighty‐one of 150 patients (54.0%) who were enrolled in the core 
study entered the extension. Thirty‐nine (48.1%) patients completed 
the extension (ie received ≥ 12 months’ treatment during the exten‐
sion and had opportunity to enter a separate long‐term pasireotide 
safety study; Figure 1); each of these patients opted to enrol in the 
separate long‐term safety study (results will be published sepa‐
rately). The remaining 42 (51.9%) patients discontinued long‐acting 
pasireotide during the extension: 25 (30.9%) discontinued prior to 
month 24 and 17 (21.0%) discontinued after month 24. The most 
common reasons for discontinuation during the extension phase 
were consent withdrawal (16.0%), unsatisfactory therapeutic effect 
(14.8%) and AEs (9.9%).
Median duration of pasireotide exposure from study start until 
end of extension was 23.9 months (range: 12.0‐55.3). At extension 
F I G U R E  1   Patient disposition. *Reasons for not entering the extension were not recorded; †The death occurred 16 d after the 16th 
injection and was not suspected by the treating physician to be related to pasireotide11; ‡Patients were considered to have completed 
the extension if both of the following criteria were met: they had received an additional ≥12 mo of treatment during the extension; and 
the core study had been unblinded, which occurred once all 150 patients who were enrolled in the core study had reached month 12 or 
discontinued treatment. The AEs leading to discontinuation in 8 patients during the extension phase were as follows: diabetes mellitus, 
n = 2; hyperglycaemia, n = 3 (one of these patients also had increased gamma‐glutamyltransferase); hyperkalaemia, n = 1; endometrial 
cancer, n = 1; and acute cholecystitis, cholelithiasis, elevated liver enzymes, bilirubin increased, oedematous pancreatitis and ascites, n = 1 
[Colour figure can be viewed at wileyonlinelibrary.com]
Entered core study (n = 150)
Completed 12-month core study (n = 104)
Entered extension study (n = 81) Did not enter extension study (n = 23)*
Completed extension study (n = 39)‡
Discontinued during the extension, n = 42
 Consent withdrawal, n = 13
 Unsatisfactory therapeutic effect, n = 12
 Adverse events, n = 8
 Administrative problems, n = 4 
 Abnormal laboratory values, n = 3
 Protocol deviation, n = 1
 Death (cardiorespiratory failure), n = 1†
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start, long‐acting pasireotide was administered at a dose of 5, 10, 30 
and 40 mg every 28 days in 6, 15, 20 and 40 patients, respectively. 
During the extension, 12 (14.8%) patients had ≥1 dose level increase 
compared with the month 12 dose.
Table 1 shows the characteristics at core and extension baseline 
for the 81 patients who entered the extension.
3.2 | Long‐term efficacy
3.2.1 | Change in mUFC and other biochemical 
markers of CD
At extension start, 42 (51.9%) patients had controlled mUFC 
(≤ULN). Eleven (13.6%) patients had partially controlled mUFC 
(>ULN but ≥50% decrease from core baseline), and 28 (34.6%) had 
uncontrolled mUFC (>ULN and <50% decrease from core baseline) 
but were considered to have been receiving clinical benefit from 
pasireotide treatment. Most patients (75.0%; n = 21/28) with un‐
controlled mUFC at extension had mUFC ≤ ULN on ≥1 visit during 
the core study.
Overall, 38/81 (46.9%) patients had controlled mUFC at month 
24 (after 12 months of treatment during the extension). The propor‐
tion of patients with controlled or partially controlled mUFC levels 
was stable from extension baseline to month 24 (Figure S1). Of the 
42 patients with controlled mUFC at extension baseline, 27 (64.3%) 
had controlled mUFC at month 24, two (4.8%) had partially con‐
trolled mUFC, and three (7.1%) had uncontrolled mUFC; 10 (23.8%) 
had discontinued or did not have an mUFC assessment at month 24. 
Eleven of 39 (28.2%) patients with mUFC > ULN at extension base‐
line had controlled mUFC at month 24; each of these patients had 
mUFC ≤ ULN on ≥1 visit during the core study.
Of patients who received 36 months’ treatment, 13/18 (72.2%) 
had controlled mUFC at this time point. At the time of each patient's 
last available assessment, 43/81 (53.1%) patients were controlled, 
16/81 (19.8%) were partially controlled and 22/81 (27.2%) were 
uncontrolled.
For patients with evaluable assessments, median mUFC levels 
remained within the normal range (15.9‐166.5 nmol/24 h) from ex‐
tension baseline up to month 36 (Figure 2). For the subset of patients 
who received ≥12 and ≥24 months’ treatment during the extension, 
median mUFC levels remained within the normal range from exten‐
sion baseline up to these time points. Median (range) change in mUFC 
from start of pasireotide treatment was −180.3 nmol/24 h (−1520.0, 
667.7; n = 81 [−51.9% change]) at month 12, −236.4 nmol/24 h 
(−1541.8, 1109.3; n = 58 [−64.1%]) at month 24, and −267.2 nmol/24 h 
(−543.0, −21.1; n = 18 [−68.3%]) at month 36. Median (range) change 
in mUFC from extension baseline to last available assessment was 
−7.7 nmol/24 h (−651.2, 667.3; n = 78 [−5.9% change]).
Median levels of morning plasma ACTH, morning serum corti‐
sol and LNSC were below core baseline levels at each 3‐monthly 
assessment during the extension (Figure 2 and Appendix S1), with 
levels within the normal range for plasma ACTH and morning serum 
cortisol at most time points. Median LNSC levels decreased from 
2.6 × ULN (n = 72) at core baseline to 2.0 × ULN (n = 71) at extension 
baseline, 1.4 × ULN (n = 55) at month 24 and 1.3 × ULN (n = 18) at 
month 36.
3.2.2 | Changes in pituitary tumour volume
Thirty‐four (42.0%) and 26 (32.1%) patients had a measurable micro‐
adenoma or macroadenoma, respectively, on MRI at start of pasire‐
otide treatment; an adenoma was not visible in 19 (23.5%) patients. 
Of patients with a measurable adenoma at core baseline and month 
24 (n = 35), 85.7% had a ≥20% reduction (n = 12; 34.3%) or <20% 
change (n = 18; 51.4%) in tumour volume between these time points 
(Table S1). No patient with a macroadenoma at study baseline had a 
≥20% increase in tumour volume at month 24 or 36.
3.2.3 | Change in clinical signs of 
hypercortisolism and health‐related QoL
Improvements in median SBP, DBP, BMI and waist circumference 
were sustained during the extension (Figure 3). For the 81 patients 
TA B L E  1   Summary of baseline characteristics for patients who 
entered the extension phase (N = 81)
Characteristic
Core baseline 
(month 0)
Extension base‐
line (month 12)
Mean age, years (SD) 39.7 (12.8) 40.7 (12.8)
Females, n (%) 61 (75.3) 61 (75.3)
Median time since diagnosis, 
months (IQR)
26.9 (9.3‐65.9) 37.9 (20.5‐77.0)
Pituitary adenoma, n (%)* 
Nonvisible adenoma 19 (23.5) 17 (21.0)
Microadenoma 34 (42.0) 41 (50.6)
Macroadenoma 26 (32.1) 17 (21.0)
Missing 2 (2.5) 6 (7.4)
Baseline mUFC, × ULN
Mean (SD) 2.6 (1.5) 1.4 (1.3)
Median (IQR) 2.3 (1.5‐3.4) 1.0 (0.7‐1.8)
Previous treatment, n (%)
Previous pituitary surgery 67 (82.7) 67 (82.7)
Medical therapy 32 (39.5) 81 (100)
Diabetic status, n (%)† 
Normal glucose tolerance 35 (43.2) 6 (7.4)
Prediabetic 14 (17.3) 9 (11.1)
Diabetic 32 (39.5) 66 (81.5)
Abbreviations: IQR, interquartile range; SD, standard deviation.
*Pituitary adenoma size defined according to maximum tumour diame‐
ter (microadenoma >0–<10 mm; macroadenoma ≥10 mm). 
†Diabetic status defined as follows: diabetic, patients with 
HbA1c ≥ 6.5%, FPG ≥ 126 mg/dL, prior history of diabetes mellitus, or 
receiving antidiabetic medication; prediabetic, patients not qualifying as 
diabetic and FPG >100–<126 mg/dL or HbA1c >5.7–<6.5%; and normal 
glucose tolerance, patients not qualifying as diabetic or prediabetic. 
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who entered the extension phase, median (range) changes from start 
of treatment to the end of the core study (month 12) were as follows: 
SBP, −4.0 mm Hg (−45.3, 27.3; n = 80); DBP, −2.0 mm Hg (−48.0, 
19.3; n = 80); waist circumference, −5.0 cm (−38.0, 34.0; n = 75); 
and BMI, −1.9 kg/m2 (−11.2, 3.5; n = 80). Median (range) changes 
from extension baseline to last available assessment were as follows: 
SBP, 2.7 mm Hg (−41.7, 27.3; n = 79); DBP, 0.0 mm Hg (−22.0, 22.0; 
n = 79); waist circumference, 1.0 cm (−13.0, 21.0; n = 77); and BMI, 
0.1 kg/m2 (−5.7, 4.1; n = 79).
Forty‐five (55.6%) patients were receiving antihypertensive med‐
ication at extension baseline. Five patients received ≥1 additional 
agent, and two initiated antihypertensive medication during the 
extension. Conversely, five patients who were on antihypertensive 
medication at extension baseline were receiving ≥1 fewer agent at 
their last visit, one of whom was not receiving any blood pressure–
lowering medication.
There were no clear changes in blood lipid levels or BMD (left 
total hip and lumbar spine) over 36 months’ treatment (Table S2). In 
total, 27 (33.3%) patients were receiving lipid‐lowering medication 
at extension baseline, none of whom had an increase in the number 
of prescribed medications during the extension. Four additional pa‐
tients started lipid‐lowering drugs during the extension.
Median (range) CushingQoL score was 41.7 (6.3, 81.3; n = 79) 
prior to starting pasireotide. Median (range) CushingQoL score im‐
proved from core study baseline by 9.4 points (−31.3, 56.3; n = 78) 
at month 12, 8.3 points (−31.3, 29.2; n = 57) at month 24, and 10.4 
F I G U R E  2   Median mUFC, ACTH, serum cortisol and LNSC over time, by duration of pasireotide treatment. Continuous lines represent 
data collected during the extension; dashed lines represent data collected during the core study for patients who were later enrolled in the 
extension. Horizontal reference lines represent the ULN range for mUFC (166.5 nmol/24 h), morning plasma ACTH (45.4 ng/L), morning 
serum cortisol (532.2 nmol/L) and LNSC (3.2 nmol/L). The number of patients contributing to the median is displayed under the X axis
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points (−27.1, 31.3; n = 17) at month 36. Median (range) change in 
CushingQoL score from extension baseline to last observed value 
was −2.1 points (−52.1, 27.1; n = 76).
3.3 | Long‐term safety
Most patients (74; 91.4%) experienced one or more AEs during the 
extension. Grade 3/4 events were reported in 31 (38.3%) patients 
(Table 2). Hyperglycaemia (23.5%) was the most commonly reported 
AE during the extension. When all AE terms related to hyperglycaemia 
were grouped, 32 (39.5%) patients experienced any hyperglycaemia‐
related AE during the extension, which led to discontinuation in three 
patients. Fifty‐eight (71.6%) patients experienced a hyperglycae‐
mia‐related AE during the 12‐month core study. Other common AEs 
(≥15% of patients) during the extension were nasopharyngitis (19.8%), 
cholelithiasis (18.5%) and diarrhoea (17.3%). Except for nasopharyn‐
gitis, these AEs occurred in fewer patients during the extension than 
the core study (Table 2). Gastrointestinal AEs were also less common 
during the extension than the core study: diarrhoea (17.3% vs 34.6%), 
nausea (9.9% vs 22.2%) and abdominal pain (2.5% vs 14.8%).
Sixteen (19.8%) patients experienced a gallbladder/biliary tract–re‐
lated AE during the extension, most commonly cholelithiasis (n = 15). 
One patient discontinued treatment because of cholelithiasis, in‐
creased blood bilirubin, and acute cholecystitis. Three (3.7%) patients 
experienced bradycardia‐related AEs during the extension, none of 
which led to discontinuation. Liver safety–related AEs occurred in nine 
(11.1%) patients, with four discontinuing treatment: increased hepatic 
enzymes with concomitant AEs of acute pancreatitis and acute cho‐
lecystitis, n = 1; increased hepatic enzymes, n = 1 (drug‐induced liver 
injury not objectified in clinical or subsequent laboratory findings); in‐
creased gamma‐glutamyltransferase with a concomitant AE of hyper‐
glycaemia, n = 1; and increased alanine aminotransferase, n = 1.
One patient died from cardiac failure during the extension. This 
death was previously reported as part of the core study analysis,11 as 
the patient died before unblinding of the core study. The death was 
not suspected to be study drug related.
F I G U R E  3   Median SBP, DBP, waist circumference and BMI, by duration of pasireotide treatment. Continuous lines represent data 
collected during the extension; dashed lines represent data collected during the core study for patients who were later enrolled in the 
extension
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For patients who entered the extension, mean HbA1c and FPG 
levels increased from core baseline to month 12 (extension base‐
line). Mean HbA1c and FPG levels were stable during the extension 
(Figure 4). Mean (95% CI) changes in HbA1c and FPG from extension 
baseline to last observed value were 0.0% (−0.2, 0.2; n = 77) and 
−6.6 mg/dL (−14.5, 1.3; n = 78), respectively.
At extension baseline, 66 (81.5%), nine (11.1%) and six (7.4%) pa‐
tients were classified as diabetic, prediabetic and normoglycaemic. At 
last available assessment, no patients had shifted from normoglycae‐
mic to prediabetic/diabetic, while six (66.7%) had shifted from predia‐
betic to diabetic. Twelve patients (14.8%) had HbA1c ≥ 8% at their last 
assessment; nine of these patients had HbA1c ≥ 8% at extension base‐
line. One patient had shifted from prediabetic to normoglycaemic at 
their last assessment. Overall, 50/81 (61.7%) patients were receiv‐
ing antidiabetic medication at extension baseline (one medication, 
n = 21; two medications, n = 14; three or more medications, n = 15). At 
last assessment, an increase in antidiabetic medications was reported 
in 10/35 (28.6%) patients. Eight of 31 (25.8%) patients who were not 
receiving antidiabetic drugs at month 12 were being treated with 
antidiabetic medication at their last assessment. Seventeen (21.0%) 
patients were receiving insulin at extension baseline; a further 10 
(12.3%) patients started insulin therapy during the extension.
4  | DISCUSSION
In this large, prospective, extension study, patients were treated 
with long‐acting pasireotide for a median of 2 years, allowing robust 
interpretation of its long‐term efficacy and safety. Long‐acting pa‐
sireotide provided sustained biochemical improvements and clini‐
cal benefit in a significant proportion of patients with CD and was 
generally well tolerated, with no new safety signals emerging over 
long‐term treatment.
Achieving and maintaining normal cortisol levels is a key treat‐
ment goal for patients with CD in order to prevent or alleviate the 
clinical signs and complications of hypercortisolism and improve 
life expectancy.8 Almost half (47%) of patients who entered this 
extension study had controlled mUFC after 2 years of long‐acting 
pasireotide treatment; 25% (n = 38/150) of patients who were en‐
rolled in the core study had controlled mUFC at month 24. Baseline 
characteristics for patients who entered this extension study were 
similar to those reported previously for all patients who participated 
in the initial core phase of the study (N = 150).11 Patients could 
continue receiving pasireotide beyond month 24 until there was an 
option to enter a separate long‐term study of pasireotide. Over two‐
thirds (72.2%; n = 13/18) of patients who were still participating in 
the extension at month 36 had controlled mUFC at this time point. 
Furthermore, over half (53%) of patients who entered the extension 
had a normal mUFC level at their last assessment, which was mar‐
ginally higher than the proportion of responders at extension start. 
These results support the long‐term efficacy of pasireotide and 
are consistent with findings from a Phase III study, in which 69% 
(n = 11/16) of ongoing patients had controlled mUFC after 5 years 
of twice‐daily, subcutaneous pasireotide therapy.14,15 Improvements 
in median mUFC, morning serum cortisol and LNSC levels were 
reported overall and for patients who received ≥2 or ≥3 years of 
AE, n (%)
Months 0‐12 After month 12
All grades Grade 3/4 All grades Grade 3/4
Total 80 (98.8) 33 (40.7) 74 (91.4) 31 (38.3)
Hyperglycaemia 32 (39.5) 4 (4.9) 19 (23.5) 3 (3.7)
Nasopharyngitis 14 (17.3) 0 16 (19.8) 0
Cholelithiasis 23 (28.4) 1 (1.2) 15 (18.5) 2 (2.5)
Diarrhoea 28 (34.6) 0 14 (17.3) 0
Urinary tract 
infection
6 (7.4) 0 10 (12.3) 0
Headache 11 (13.6) 0 9 (11.1) 0
Diabetes mellitus 15 (18.5) 7 (8.6) 8 (9.9) 4 (4.9)
Nausea 18 (22.2) 0 8 (9.9) 0
Hypoglycaemia 10 (12.3) 2 (2.5) 8 (9.9) 2 (2.5)
Fatigue 11 (13.6) 0 7 (8.6) 0
Dizziness 11 (13.6) 1 (1.2) 6 (7.4) 0
Abdominal pain 12 (14.8) 0 2 (2.5) 1 (1.2)
Influenza 11 (13.6) 0 5 (6.2) 0
Oedema peripheral 10 (12.3) 0 5 (6.2) 0
Note: AEs are sorted in descending order of events during the extension. Patients who experienced 
an AE during the core study (months 0‐12) and the extension (after month 12) are counted in both 
columns.
TA B L E  2   AEs (≥10% of patients during 
the core or extension phase), regardless of 
drug relationship, in the 81 patients who 
entered the extension
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treatment. Unlike mUFC and morning serum cortisol, median LNSC 
remained >ULN during the extension. Additional studies are needed 
to examine the effect of cortisol‐lowering therapies on salivary cor‐
tisol and the role of LNSC in monitoring medical treatment response.
Cardiovascular disease is the leading cause of death in patients 
with CD.16 Consequences of cortisol excess that can contribute to 
cardiovascular disease include hypertension, truncal obesity, impaired 
glucose tolerance, insulin resistance, dyslipidaemia and hypercoagula‐
bility.17 In our study, improvements in blood pressure, BMI and waist 
circumference were maintained for up to 3 years of pasireotide treat‐
ment. Such improvements may confer a reduction in mortality risk, 
given that small reductions in blood pressure can significantly reduce 
the risk of cardiovascular events in patients with hypertension.18 
Contrary to previous reports, we did not observe any consistent 
changes in cholesterol or triglycerides during our study.18,19
It is important to note that concomitant medications were 
allowed during this study, which could have contributed to the 
observed changes in clinical signs over time. Persistent hypercor‐
tisolism is associated with progressive bone degradation resulting 
in increased fracture risk for patients with CD.20 Encouragingly, 
BMD was stable throughout 36 months of pasireotide treatment, 
although additional studies are warranted to confirm the effects of 
pasireotide on the prevention/reversal of bone deterioration in pa‐
tients with CD.
Hypercortisolism and its clinical effects detrimentally impact 
on QoL; the effects often persist after the resolution of hypercor‐
tisolism.21 Patients who participated in the current extension had 
significantly impaired QoL (CushingQoL score, 41.7 points) prior 
to starting treatment with long‐acting pasireotide. Importantly, 
CushingQoL score improved from baseline over 3 years of treat‐
ment, potentially reflecting the improvements in clinical signs of hy‐
percortisolism during pasireotide treatment.
Pituitary tumour volume decreased or remained stable in most 
patients during long‐term treatment with pasireotide, consistent 
with previous reports.22‐25 Given its tumour‐shrinkage effects, it 
has been proposed that pasireotide may be particularly beneficial 
in patients with a clinically relevant tumour mass and/or tumour 
progression.9,10,26 This assertion is supported by our findings that 
almost half (46%; n = 6/13) of patients with a macroadenoma before 
initiation of pasireotide treatment had a significant (≥20% change) 
decrease in tumour volume by month 24, with the remainder exhib‐
iting stable tumour size.
The safety profile of long‐acting pasireotide during this extension 
was similar to that during the core study, with no new safety signals 
emerging. AEs were generally mild/moderate and occurred less fre‐
quently in the extension than in the first 12 months of treatment. The 
lower rate of AEs in the extension phase than in the core study may be 
explained by the early onset and effective management of side effects 
during pasireotide treatment, while patients who tolerated pasireotide 
may have been more likely to continue into the extension phase. These 
findings are similar to those of a previous prospective study of subcuta‐
neous twice‐daily pasireotide, in which AEs related to hyperglycaemia, 
liver safety, the gallbladder and bradycardia tended to emerge during 
the first 6 months of treatment and did not usually worsen over 5 years’ 
treatment.14
According to the American Diabetes Association and European 
Association for the Study of Diabetes, glycaemic targets should be 
individualized based on key patient characteristics. As such, while 
an HbA1c level of <7% represents a reasonable goal for many adults, 
less stringent targets (such as <8%) are appropriate in some patients, 
such as those with extensive comorbid conditions.27,28 In our study, 
mean HbA1c and FPG levels were stable; mean HbA1c remained 
<7% over the course of the extension, and most (85%) patients had 
HbA1c < 8.0% at their last assessment.
Initiation and escalation of antidiabetic therapy was at the dis‐
cretion of the investigator; 26% of patients who were not receiving 
antidiabetic therapy at extension baseline were receiving at least 
one agent at their last assessment, while 29% of patients who were 
already receiving 1‐2 antidiabetic drugs were receiving at least one 
additional agent. Taken together, these findings demonstrate that if 
hyperglycaemia occurs, it tends to emerge soon after initiation of 
F I G U R E  4   Mean (SD) FPG and HbA1c levels during the 
extension phase. Continuous lines represent data collected during 
the extension; dashed lines represent data collected during the core 
study for patients who were later enrolled in the extension
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pasireotide and can be effectively managed in some patients with 
antidiabetic therapy.
Few studies have examined the efficacy and safety of long‐term 
treatment with other medical therapies for CD. In a retrospective 
analysis of 51 patients who had received long‐term (≥2 years) ke‐
toconazole treatment, a normal mUFC level was seen in 65% of 
patients at their last available assessment, with clinical improve‐
ments seen in hypertension, diabetes and hypokalaemia.29 One‐fifth 
(20.5%) of patients discontinued treatment because of intolerance.29 
In a retrospective analysis of metyrapone treatment, 64% (n = 9/14) 
of patients who had an available mUFC assessment after ≥6 months 
of treatment had a normal mUFC level at their last available as‐
sessment, while there was a low incidence (11%; n = 4/38) of AEs 
in these patients.30 In another retrospective study, 40% (n = 21/53) 
of patients receiving cabergoline therapy initially achieved normal 
UFC levels, with treatment escape seen in 39% (n = 7/18) of patients 
who remained on treatment for ≥12 months.31 Published data on 
mifepristone and osilodrostat are limited to shorter durations of 
treatment.32,33 The choice of medical treatment options should be 
tailored to the individual clinical situation, taking into consideration 
the patient, disease and tumour characteristics.8
5  | CONCLUSIONS
Patients who entered this extension study exhibited sustained bio‐
chemical and clinical benefit over 3 years of treatment with long‐
acting pasireotide, which was accompanied by improvements in QoL 
and tumour size control. The long‐term safety profile of pasireotide 
was favourable and consistent with that reported during the first 
12 months of treatment. These data support the use of long‐acting 
pasireotide as an effective long‐term treatment option for some pa‐
tients with CD.
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